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Abstract 
Nodal marginal zone lymphoma (NMZL) is a 
primary nodal B-cell neoplasm that morphlogically 
resembles lymph nodes involved by MZL of 
extranodal or splenic types. Two 
clinicopathological forms of NMZL are recognized: 
adult type and pediatric-type. NMZLs show 
overlapping features with other types of MZL, but 
distinctive features as well. NMZL remains an 
enigmatic entity with accompanying difficulties in 
diagnosis and a lack of knowledge of prognosis and 
treatment. 
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Disease 
Nodal marginal zone lymphoma (NMZL) is a 
primary nodal B-cell neoplasm that morphlogically 
resembles lymph nodes involved by MZL of 
extranodal or splenic types, but without evidence of 
extranodal or splenic disease. Presence of a primary 
extranodal MZL should be ruled out since 
approximately one third of the cases presenting as 
NMZL represent nodal dissemination of a MALT 
lymphoma.  
NMZL can also be diagnosed in children, which 
has distinct clinical and morphological features 
with an excellent prognosis (Swerdlow, et al ,2008. 
Swerdlow, et al, 2016). 
Phenotype/cell stem origin 
The postulated normal counterpart of NMZL is 
post-germinal centre marginal zone B-cell 
(Swerdlow, et al , 2008).  
NMZL expresses pan-B-cell markers with CD43 
coexpression in 50% of the cases. CD5, CD23, 
CD10, bcl6 and cyclinD1 are negative and bcl2 is 
positive in most cases.  
Tumors mimicking splenic MZL have a similar 
phenotype but are usually IgD positive (Swerdlow, 
et al , 2008. Swerdlow, et al, 2016; Campo, et al, 
1999). A reported case showed unusual 
immunophenotypic findings for NMZL with 
monotypic kappa-positive B cells demonstrating 
CD5, CD23, and BCL6 coexpression (Aquil, et al, 
2015). 
Epidemiology 
NMZL comprises only 1.5-1.8% of all lymphoid 
neoplasms. The reported incidence ranges from 
5.7/1,000,000 person-years to 8. 3/1,000,000 
person-years, and steadily increased by 25% during 
2001-2005 and 2006-2009 (Khalil, et al. 2014, 
Tadmor, et al, 2017). Most cases occur in adults 
with a median age around 60 years and a similar 
proportion in males and females.  
Paediatric NMZL predominantly present in males 
(ratio 20:1) with asymtomatic and localized (90% 
stage I) disease, mainly in the head and neck lymph 
nodes (Swerdlow, et al ,2008. Swerdlow, et al, 
2016). 
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Clinics 
Most patients present with asymptomatic, localized 
or generalized peripheral lymphadenopathy. The 
sites of involvement are peripheral lymph nodes, 
occasionally bone marrow and peripheral blood 
(Swerdlow, et al ,2008. Swerdlow, et al, 2016). 
Elevated LDH (lactate dehydrogenase) levels are 
indicative of a less favorable prognosis, and in 
these cases high grade transformation must be 
excluded (Tadmor, et al, 2017). About 20-40% of 
patients with NZML develop B-symptoms and 
performance status is overall good. A serum M-
component is present in 10% of patients (Pileri, et 
al, 2017). Hepatitis C virus (HCV) has been 
reported in a subset of NMZL patients. 
Autoimmune diseases are associated with NMZL, 
including rheumatoid arthritis, vitiligo, systemic 
lupus erythematosus, autoimmune hemolytic 
anemia, chronic thyroiditis, and Sjögren's syndrome 
(van den Brand, et al,2013). 
Pathology 
NMZL is frequently a diagnosis of exclusion, 
including reactive hyperplasia and indolent small B  
cell lymphoma. Morphologically, the tumor cells 
surround reactive follicles and expand into the 
interfollicular areas.  
Follicular colonization may be present. In cases 
with a diffuse pattern, follicle remnants may be 
detected with stains for follicular dendritic cells and 
germinal centre markers.  
The tumour cells are composed of variable numbers 
of marginal zone (centrocyte-like and monocytoid) 
B-cells, plasma cells and scattered transformed B-
cells. Diagnosis of transformation requires the 
identification of sheets of large cells. Plasma cell 
differentiation may be prominent and the 
differential diagnosis with lymphoplasmacytoma 
may be difficult. The presence of remnants of 
follicular dendritic meshworks suggestive of 
colonized follicles would favour the diagnosis of 
NMZL.  
In paediatric NMZL, the tumor is similar to that 
seen in adults except that there are often 
progressively transformed germinal centers in 
which the outer border of the follicles is disrupted 
and infiltrated by tumor cells (Swerdlow, et al , 
2008. Swerdlow, et al, 2016). 
 
 
Figure 1.  Nodal marginal zone lymphoma. At low magnification, nodular growth pattern with pale cell can be seen (HE staining). 
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Figure 2.  The tumor cells are small to medium in size, with pale cytoplasm (HE staining) 
 
 
Figure 3.  The tumor cells are small to medium in size, with small nucleoli in some cells (HE staining) 
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Figure 4.  The cells are positive for CD20. 
 
 
Figure 5.  The proliferation index of Ki67 is low in tumor cells, with residual germinal centers. 
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Treatment 
Until now the clinical approach has in fact been 
adapted from those applied and one recommended 
for other indolent lymphomas. In NMZL, treatment 
is not always required in asymptomatic patients 
NMZL and like with other low grade lymphomas, a 
"watch and wait" policy may well be a reasonable 
option. In symptomatic patients requiring treatment, 
the therapeutic approach will differ based on 
whether the disease is localized or more systemic. 
For localized disease, surgery followed by 
radiotherapy is a possible option (Tadmor, et al, 
2017). Targeted therapies against deregulated 
molecular pathways are an attractive field of 
investigation, but definitive data about this 
approach are not yet available. The research 
includes B-cell receptor, JAK/STAT, NF-kB, 
NOTCH, and Toll-like receptor signaling pathways, 
as well as intracellular processes such as the cell 
cycle, chromatin remodeling, and transcriptional 
regulation in terms of epigenetic modifiers, 
histones, or transcriptional co-repressors, along 
with immune escape via T-cell-mediated tumor 
surveillance (Pileri et al, 2017. Thieblemont et al, 
2016). Bendamustine plus rituximab was found to 
be an active and well-tolerated regimen leading to 
the rapid control of disease (Laribi, et al, 2017). 
Prognosis 
60-80% of the patients survive longer than 5 years. 
The prognosis of these patients may be predicted 
using the follicular lymphoma international 
prognostic index (FLIPI). Other prognostic values 
for NMZL include age >60 years, the presence of 
B-symptoms, elevated LDH, levels, and cyclin 
expression. The mean 5-year OS in published series 
is 62-90% (Swerdlow, et al ,2008. Swerdlow, et al, 
2016. Tadmor, et al, 2017).  
The prognosis of paediatric NMZL is excellent with 
a very low relapse rate and long survival after 
conservative treatment (Swerdlow, et al , 2008. 
Swerdlow, et al, 2016). Aquil et al. described a 
unique case of childhood NMZL with unusual 
clinicopathologic features for the pediatric variant 
including generalized lymphadenopathy, high-stage 




The immunoglobulin genes are clonally rearranged 
with a predominance of mutated VH3 and VH4 
families. Trisomies 3, 18 and 7 have been observed. 
The translocations associated with extranodal MZL 
are not detected (Swerdlow, et al , 2008. Swerdlow, 
et al, 2016).  
Unique chromosomal abnormalities including 
monosomy 20 and add(10)(p11.2) can be seen in a 
paediatric case (Aquil, et al, 2015).  
Gene expression profiling analysis has 
demonstrated an increased expression of NFkB 
related genes. Some genetic defects in NMZL have 
been reported, including KMT2B (MLL2), PTPRD, 
NOTCH2, and KLF2. With the exception of MLL2, 
which is present in more than one third of cases, the 
other affected genes occur in about 20% of cases. 
NMZL harbored PTPRD lesions as an ovelmarker 
for this lymphoma across mature B-cell tumors, and 
support the distinction of NMZL as an independent 
clinicopathologic entity within the current 
lymphoma classification (Pileri, et al, 2017). 
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